Historically, the selection of the most effective adjuvant regimen for breast cancer patients was based on tumor size and nodal status but this approach took into account the stage only, without considering that the biology of the tumor matters as well, as breast cancer is a heterogeneous disease at the molecular level. In the present manuscript we will attempt to address the issue of selecting the most appropriate cytotoxic agents for adjuvant programs in the clinically and biologically distinct subgroups of endocrine responsive (luminal A and luminal B), HER2 positive and triple negative breast cancer patients.
Optimal adjuvant chemotherapy in breast cancer : selection of agents / A. Esposito, C. Criscitiello, E. Omodeo Salè, G. Curigliano. - In: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. - ISSN 1751-2433. - 7:5(2014), pp. 605-611.
Optimal adjuvant chemotherapy in breast cancer : selection of agents
C. Criscitiello;G. Curigliano
Writing – Original Draft Preparation
2014
Abstract
Historically, the selection of the most effective adjuvant regimen for breast cancer patients was based on tumor size and nodal status but this approach took into account the stage only, without considering that the biology of the tumor matters as well, as breast cancer is a heterogeneous disease at the molecular level. In the present manuscript we will attempt to address the issue of selecting the most appropriate cytotoxic agents for adjuvant programs in the clinically and biologically distinct subgroups of endocrine responsive (luminal A and luminal B), HER2 positive and triple negative breast cancer patients.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.